$TAK

Greenway Nicola Deidre Petal sold $116K of TAK

Greenway Nicola Deidre Petal (Chief Human Resources Officer) sold 6,774 shares of TAKEDA PHARMACEUTICAL CO LTD (TAK) at $17.10 ($0.12M total) on 2026-08-10.

Original reporting
SEC EDGAR · Greenway Nicola Deidre Petal
Published Aug 13, 2026, 1:28 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 13, 2026, 1:32 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$TAK
Neutral
medium confidence
Mentioned
$TAK
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TAKNeutralLow
01

Why it matters

The newest fact is the CHRO’s open-market sale details (shares, price, total value, and post-transaction holdings).

02

Market read

Traders may note the insider sale, but there is no accompanying fundamental catalyst in the text.

03

What to watch

Insider sales can be driven by diversification, tax planning, or pre-existing personal liquidity needs; the filing provides no motive or forward-looking information.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-12, transaction dated 2026-08-10

Background

This is an SEC Form 4 insider transaction disclosure for Takeda Pharmaceutical Co Ltd.

Company-level read

Ticker impact

$TAKNeutralMedium confidence
Context

Takeda disclosed an insider open-market sale by its CHRO, Greenway Nicola Deidre Petal, of 6,774 shares at $17.10.

Expected impact

Likely minimal near-term impact; any effect would be sentiment-driven and small versus normal insider activity.

Evidence & confidence

Form 4 provides transaction details (size, price, post-sale holdings) but no accompanying company guidance, operational update, or regulatory/legal catalyst.

Market effects

Insider selling in a large pharma name is not a sector-level signal without additional context.

None indicated; the disclosure is company-specific.

None indicated; no cross-border deal, trial, or regulatory action is described.

Counterpoint

Absence of a stated 10b5-1 plan could be interpreted as less “scheduled,” but the disclosed sale size is still modest relative to typical institutional flows.

Key entities

  • Takeda Pharmaceutical Co Ltd

    Subject of the Form 4 insider transaction disclosure.

  • Greenway Nicola Deidre Petal

    Chief Human Resources Officer who sold 6,774 shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$TAKMedAI 9/10

Why Zasocitinib Outperformed Deucravacitinib in New Plaque Psoriasis Data

Zasocitinib, an investigational TYK2 inhibitor by Takeda, showed superior efficacy in treating plaque psoriasis compared to deucravacitinib in a phase 3 trial. 36.5% of patients achieved PASI 100 with zasocitinib vs. 13.9% with deucravacitinib. The drug's higher TYK2 selectivity and longer IL-23 blockade were cited as key factors. Zasocitinib is under review by the FDA and EMA.

$TAKHighAI 9/10

Oveporexton Improves Wakefulness and Cataplexy in Narcolepsy Type 1

Takeda's Oveporexton (Orzeyful) significantly improved wakefulness, daytime sleepiness, and cataplexy in narcolepsy type 1 patients over 12 weeks, according to two phase 3 trials. The FDA approved the drug in August 2026, positioning it as the first therapy addressing orexin deficiency. Adverse events included increased urinary frequency and transient insomnia. Trials showed mean sleep latency improvements of 14.3 to 19.8 minutes with Oveporexton vs. placebo.

$TAKMedAI 8/10

Zasocitinib Delivered Superior Efficacy Versus Deucravacitinib in New Phase 3 Head-to-Head Results, Reinforcing Potential to Deliver Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill

Takeda announced Phase 3 trial results showing zasocitinib (TAK-279) demonstrated superior efficacy in treating moderate-to-severe plaque psoriasis compared to deucravacitinib. Key data: 36.5% of patients achieved complete skin clearance (PASI 100) at week 16 vs. 13.9% for deucravacitinib. Zasocitinib also showed durable skin clearance and improvements in itch and quality of life. The drug is under regulatory review for psoriasis treatment.

$TAKMedAI 9/10

Takeda Pharmaceutical Company Limited: Takeda Highlights Late-Stage Oncology Pipeline Progress and Solid Tumor Portfolio Research, Led by Late-Breaking Phase 3 Arcotatug Tavatecan (TAK-921) Data, at ESMO 2026

Takeda (TSE:4502/NYSE:TAK) will present data on its oncology pipeline at ESMO 2026, including Phase 3 results for arcotatug tavatecan in advanced gastric cancer and findings on TAK-928 for NSCLC. The company is expanding a global Phase 3 study for TAK-928.